| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,430,494 | 14 | 100 |
| Tom Penny | Principal Accounting Officer | 0 | $0 | 2 | $200,178 | $-200,178 |
| Connelly Stephen | President and CSO | 0 | $0 | 2 | $723,830 | $-723,830 |
| Zedelmayer Christine | Sr. Vice President and COO | 0 | $0 | 10 | $1.51M | $-1.51M |
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also …
Over the last 12 months, insiders at Equillium, Inc. have bought $0 and sold $2.43M worth of Equillium, Inc. stock.
On average, over the past 5 years, insiders at Equillium, Inc. have bought $0 and sold $665,724 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-06-05 | Sale | Connelly Stephen | President and CSO | 30,975 0.0809% | $2.94 | $91,070 | -23.81% | |
| 2026-06-05 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 14,584 0.038% | $2.93 | $42,737 | -23.81% | |
| 2026-06-04 | Sale | Connelly Stephen | President and CSO | 200,000 0.5619% | $3.16 | $632,760 | -29.02% | |
| 2026-05-28 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 86,012 0.2386% | $2.80 | $240,693 | -20.07% | |
| 2026-05-28 | Sale | Tom Penny | Principal Accounting Officer | 65,000 0.1901% | $2.95 | $191,750 | -20.07% | |
| 2026-05-27 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 9,821 0.0284% | $2.70 | $26,517 | -13.69% | |
| 2026-03-13 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 120,312 0.3429% | $2.50 | $300,816 | -11.94% | |
| 2026-03-09 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 181,219 0.5765% | $2.00 | $362,438 | +7.43% | |
| 2026-02-19 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 185,937 0.5433% | $1.76 | $328,104 | +17.31% | |
| 2026-01-08 | Sale | Tom Penny | Principal Accounting Officer | 6,533 0.021% | $1.29 | $8,428 | +82.30% | |
| 2025-12-23 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 100,000 0.3016% | $1.50 | $150,000 | +51.48% | |
| 2025-12-15 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 11,900 0.0363% | $1.31 | $15,589 | +66.39% | |
| 2025-12-12 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 23,804 0.0702% | $1.34 | $31,897 | +57.81% | |
| 2025-11-25 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 8,098 0.0226% | $0.95 | $7,696 | +112.97% | |
| 2025-01-23 | Sale | Keyes Jason A | Chief Financial Officer | 10,000 0.0275% | $0.65 | $6,500 | +23.15% | |
| 2024-11-14 | Sale | Keyes Jason A | Chief Financial Officer | 10,000 0.0286% | $0.70 | $7,000 | +3.37% | |
| 2024-10-28 | Sale | Zedelmayer Christine | Sr. Vice President and COO | 15,000 0.0481% | $1.25 | $18,750 | -48.25% | |
| 2024-10-28 | Sale | Tom Penny | Principal Accounting Officer | 2,835 0.0091% | $1.25 | $3,544 | -48.25% | |
| 2024-10-25 | Sale | Tom Penny | Principal Accounting Officer | 683 0.0022% | $1.25 | $854 | -40.44% | |
| 2024-09-26 | Sale | Keyes Jason A | Chief Financial Officer | 10,000 0.0286% | $0.81 | $8,100 | -10.91% |
| Increased Positions | 23 | +52.27% | 10M | +34.46% |
| Decreased Positions | 18 | -40.91% | 2M | -8.28% |
| New Positions | 8 | New | 6M | New |
| Sold Out Positions | 11 | Sold Out | 2M | Sold Out |
| Total Postitions | 49 | +11.36% | 36M | +26.18% |
| Adar1 Capital Management, Llc | $8,507.00 | 9.12% | 5.56M | +6M | New | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $8,154.00 | 8.74% | 5.33M | +5M | New | 2025-09-30 |
| Decheng Capital Llc | $6,804.00 | 7.29% | 4.45M | 0 | 0% | 2025-09-30 |
| Woodline Partners Lp | $5,368.00 | 5.75% | 3.51M | +4M | New | 2025-09-30 |
| Balyasny Asset Management L.P. | $3,066.00 | 3.29% | 2M | +2M | New | 2025-09-30 |
| Stempoint Capital Lp | $2,921.00 | 3.13% | 1.91M | +2M | New | 2025-09-30 |
| Vanguard Group Inc | $2,010.00 | 2.15% | 1.31M | +489,855 | +59.44% | 2025-09-30 |
| Renaissance Technologies Llc | $941.00 | 1.01% | 614,923 | +340,823 | +124.34% | 2025-09-30 |
| Cota Capital Management, Llc | $860.00 | 0.92% | 562,278 | 0 | 0% | 2025-06-30 |
| Cantor Fitzgerald, L. P. | $650.00 | 0.7% | 425,000 | +425,000 | New | 2025-09-30 |